Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
Neurocrine Bio. (NBIX) PT Raised to $100 at Baird After Another Beat for Ingrezza
May 1, 2018 7:15 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $84.00) while maintaining an Outperform rating following another strong quarter for Ingrezza.
Analyst Brian Skorney commented, "Investor fears about a quarter of declining sequential growth turned out to be unfounded as... More
